Most New Drugs Never Make it to Market

The amazing speed with which the pharmaceutical industry developed, tested and won emergency approval for the COVID-19 vaccine was not just surprising, but in at least one way, misleading.

As the new report, Clinical Development Success Rates and Contributing Factors 2011 – 2020 from Bio.org makes clear, the COVID vaccines and therapeutics that became available mere months into the pandemic were a dramatic and rare exception.

On average, the report tells us it takes almost 11 years to go from a Phase I program to regulatory approval. And that’s only for those drugs and therapies that make it through. Over the 10 years from 2011, the likelihood that a drug in a Phase I trial would ultimately win approval was 7.9%.

That may be better odds than winning the Powerball lottery, however, the investment in a drug’s development can dwarf all but the largest jackpots. Making it even more of a gamble for a pharmaceutical firm is that the average success rate has declined since Bio’s 2016 report. Then the average for the previous 10 years was 9.6%.

Heavy with tables, charts and graphs, the Bio.org report (in conjunction with Informa Pharma Intelligence and QLS Advisors) reviews success rates across 21 major diseases. It reports specifics on 14 of them, combining the balance into an “Other” category. The detailed diseases are: Allergy, Autoimmune, Cardiovascular, Endocrine, Gastroenterology (non-IBD), Hematology, Infectious disease, Metabolic, Neurology, Oncology, Ophthalmology, Psychiatry, Respiratory, and Urology.

Comparing the success rates in the current report to the previous one, Bio found 12 categories had a lower likelihood of progressing from Phase 1 to approval. The largest decline was in urology. In the 2016 report, therapeutics in this category averaged 11.4% success. In the recent report, the average fell to 3.6%.

Hematology has the highest likelihood of approval at 23.9%, though it too saw a decline from 26.1%.

Drugs to treat rare diseases fared better than other therapies. The report said these drugs had a 17% likelihood of success.

The decrease, explains a Bio.org discussion of the report, “Can be attributed to two main factors: A greater participation from smaller firms participating in drug candidate development and their willingness to disclose early failures.”

Said David Thomas, BIO VP, industry research, “That all ties into what we see, which is a lower success rate overall from our last paper in 2016.”

Drug development remains difficult with far less than 1 in 10 clinical drug programs ever reaching patients,” says the Bio.org account. “It usually takes 10 to 10.5 years to develop a vaccine, which makes the existing COVID-19 vaccines on the market all the more incredible.”

Success, adds Thomas, takes “many shots on goal.”

Photo by ThisisEngineering RAEng on Unsplash

Mary-Kate Bula Selected as Assistant Coach of the USA Women’s Flag Football National Team
General Interest Pharma

Mary-Kate Bula Selected as Assistant Coach of the USA Women’s Flag Football National Team

Leveraging LinkedIn Polls: A Strategic Tool for Business Insights
General Interest

Leveraging LinkedIn Polls: A Strategic Tool for Business Insights

#WeAreGreenKey: Spotlight on Kyle Gierke
General Interest Healthcare

#WeAreGreenKey: Spotlight on Kyle Gierke

Essential Strategies for 2024: Remote Training
General Interest

Essential Strategies for 2024: Remote Training

Steps to Nurture a Multigenerational Workforce
General Interest

Steps to Nurture a Multigenerational Workforce

Tips to Cultivate a Compelling Employer Brand
General Interest

Tips to Cultivate a Compelling Employer Brand

Green Key Names 3 New Partners in 2024
General Interest

Green Key Names 3 New Partners in 2024

#WeAreGreenKey: Spotlight on Samantha Desena 
Accounting + Finance General Interest

#WeAreGreenKey: Spotlight on Samantha Desena 

Why Companies are Already Recruiting Interns for 2025
General Interest

Why Companies are Already Recruiting Interns for 2025

Todd Gabianelli Selected as an Old Master at Purdue University 
Pharma

Todd Gabianelli Selected as an Old Master at Purdue University 

Navigating the Surge of Respiratory Illnesses Across the U.S.
General Interest

Navigating the Surge of Respiratory Illnesses Across the U.S.

Gen Z: Catalysts for Workplace Evolution in 2024
General Interest

Gen Z: Catalysts for Workplace Evolution in 2024

The Office Real Estate Dilemma
General Interest

The Office Real Estate Dilemma

#WeAreGreenKey: Spotlight on Rich Egloff
Architecture + Engineering Leadership + Management

#WeAreGreenKey: Spotlight on Rich Egloff

From the Big Quit to the Big Stay
General Interest

From the Big Quit to the Big Stay

Wrapped up: Green Key Unlocked 2023
Accounting + Finance Architecture + Engineering General Interest Healthcare Information Technology

Wrapped up: Green Key Unlocked 2023

Job Market Trends to Look For in 2024
General Interest

Job Market Trends to Look For in 2024

Wrapped Up: #WeAreGreenKey 2023
General Interest

Wrapped Up: #WeAreGreenKey 2023

Is Curiosity a Recruiter’s Superpower?
General Interest

Is Curiosity a Recruiter’s Superpower?

Best Practices for Performance Reviews
General Interest

Best Practices for Performance Reviews

Latest Blog Posts
View All Posts
Mary-Kate Bula Selected as Assistant Coach of the USA Women’s Flag Football National Team

Mary-Kate Bula Selected as Assistant Coach of the USA Women’s Flag Football National Team

Mary-Kate Bula, recruiter on Green Key’s Pharma team was recently selected as Assistant Coach of the USA Women’s Flag Football...
Read More
Leveraging LinkedIn Polls: A Strategic Tool for Business Insights

Leveraging LinkedIn Polls: A Strategic Tool for Business Insights

In today’s dynamic business landscape, understanding market trends, customer preferences, and industry insights is essential for staying ahead of the...
Read More
#WeAreGreenKey: Spotlight on Kyle Gierke

#WeAreGreenKey: Spotlight on Kyle Gierke

We met up with Kyle Gierke, Staffing Manager on the Healthcare team at Green Key. Kyle started his journey at...
Read More